Johnson & Johnson

YTD

ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.

CEO

Joaquin Duato

CEOJoaquin Duato

Employees

138,100

Employees138,100

Headquarters

New Brunswick, New Jersey

HeadquartersNew Brunswick, New Jersey

Founded

1887

Founded1887

Employees

138,100

Employees138,100

JNJ Key Statistics

Market cap

372.06B

Market cap372.06B

Price-Earnings ratio

26.21

Price-Earnings ratio26.21

Dividend yield

3.27%

Dividend yield3.27%

Average volume

14.68M

Average volume14.68M

High today

$155.00

High today$155.00

Low today

$152.50

Low today$152.50

Open price

$151.48

Open price$151.48

Volume

66.73K

Volume66.73K

52 Week high

$169.99

52 Week high$169.99

52 Week low

$140.68

52 Week low$140.68

JNJ News

Seeking Alpha 53m

J&J kicks off pharma earnings season with guidance raise amid looming tariffs

Johnson & Johnson (NYSE:JNJ) traded flat as the healthcare giant started pharma earnings season on Tuesday, raising its full-year sales outlook with its Q1 resu...

Sherwood News 1h

J&J beats analyst earnings estimates, offers upbeat guidance

The company doesn't think the threat of tariffs will shrink its profits in 2025. Johnson & Johnson rose in early trading after it reported earnings that beat a...

Benzinga 5h

Johnson & Johnson Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Johnson & Johnson JNJ will release earnings results for the first quarter, before the opening bell on Tuesday, April 15. Analysts expect the New Brunswick, New...

Analyst ratings

54%

of 24 ratings

Buy

45.8%

Hold

54.2%

Sell

More JNJ News

TipRanks 21h

Johnson & Johnson Stands Firm as Recession-Resistant Tariff-Proof Anchor

With recession concerns circulating in the market, Johnson & Johnson (JNJ) stock could stabilize many portfolios. Since its founding in 1886, the healthcare gia...

TipRanks 23h

Johnson & Johnson price target lowered to $162 from $165 at Raymond James

Raymond James analyst Jayson Bedford lowered the firm’s price target on Johnson & Johnson to $162 from $165 and keeps an Outperform rating on the shares ahead o...

TipRanks 1d

Options Volatility and Implied Earnings Moves This Week, April 14 – April 17, 2025

This week, several major companies will be reporting earnings. Among them are Netflix (NFLX), Bank of America (BAC), Johnson & Johnson (JNJ), Citigroup (C), ASM...

Benzinga 5d

Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study

Protagonist Therapeutics, Inc. PTGX on Thursday announced new data for a pill that treats moderate-to-severe plaque psoriasis. The Phase 3 study was conducted i...

Simply Wall St 6d

Johnson & Johnson Shares React as FDA Grants Multiple Designations to Nipocalimab

announced compelling results from its Phase 3 Vivacity-MG3 study on nipocalimab, showing promising efficacy and safety in treating generalized myasthenia gravis...

Benzinga 6d

This Johnson & Johnson Analyst Turns Bullish On Shifting Focus From Stelara Concerns To Innovative Medicine

While the consensus seems to underappreciate the trajectory of Johnson & Johnson's JNJ Innovative Medicine business, Goldman Sachs says concerns around the Stel...

Seeking Alpha 6d

J&J, Halozyme get EU nod for Darzalex SC to treat multiple myeloma

Halozyme Therapeutics (NASDAQ:HALO) announced on Wednesday that the European Commission has approved an injectable combo regimen of Darzalex, the antibody thera...